170 related articles for article (PubMed ID: 26153241)
1. Evaluation of the SIGNIFY trial.
Grassi G
Expert Opin Pharmacother; 2015; 16(12):1861-4. PubMed ID: 26153241
[TBL] [Abstract][Full Text] [Related]
2. Ivabradine in stable coronary artery disease without clinical heart failure.
Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136
[TBL] [Abstract][Full Text] [Related]
3. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure.
Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R
Am Heart J; 2013 Oct; 166(4):654-661.e6. PubMed ID: 24093844
[TBL] [Abstract][Full Text] [Related]
4. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study.
Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
Eur Heart J; 2015 Dec; 36(46):3291-6. PubMed ID: 26385957
[TBL] [Abstract][Full Text] [Related]
5. Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease.
Weeda ER; Nguyen E; White CM
Ann Pharmacother; 2016 Jun; 50(6):475-85. PubMed ID: 26917820
[TBL] [Abstract][Full Text] [Related]
6. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
[TBL] [Abstract][Full Text] [Related]
7. Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris.
Borer JS; Swedberg K; Komajda M; Ford I; Tavazzi L; Böhm M; Depre C; Wu Y; Maya J; Dominjon F
Cardiology; 2017; 136(2):138-144. PubMed ID: 27614723
[TBL] [Abstract][Full Text] [Related]
8. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
Bruguera Cortada J; Varela A
Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
[TBL] [Abstract][Full Text] [Related]
9. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
10. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
Borer JS; Deedwania PC; Kim JB; Böhm M
Am J Cardiol; 2016 Dec; 118(12):1948-1953. PubMed ID: 27780557
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
[No Abstract] [Full Text] [Related]
12. Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease.
Dillinger JG; Maher V; Vitale C; Henry P; Logeart D; Manzo Silberman S; Allée G; Levy BI
Hypertension; 2015 Dec; 66(6):1138-44. PubMed ID: 26418022
[TBL] [Abstract][Full Text] [Related]
13. [Heart rate modulation in stable ischemic heart disease: what we have learned from the SIGNIFY study?].
Perna GP; Battistoni I; Angelini L
G Ital Cardiol (Rome); 2015 Mar; 16(3):155-60. PubMed ID: 25837459
[TBL] [Abstract][Full Text] [Related]
14. Ivabradine, coronary heart disease, and heart failure: time for reappraisal.
Stulc T; Ceška R
Curr Atheroscler Rep; 2014 Dec; 16(12):463. PubMed ID: 25301354
[TBL] [Abstract][Full Text] [Related]
15. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
Danchin N
Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
[TBL] [Abstract][Full Text] [Related]
16. Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life Substudy.
Tendera M; Chassany O; Ferrari R; Ford I; Steg PG; Tardif JC; Fox K;
Circ Cardiovasc Qual Outcomes; 2016 Jan; 9(1):31-8. PubMed ID: 26696613
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction.
Cammarano C; Silva M; Comee M; Donovan JL; Malloy MJ
Clin Ther; 2016 Feb; 38(2):387-95. PubMed ID: 26839043
[TBL] [Abstract][Full Text] [Related]
18. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
[TBL] [Abstract][Full Text] [Related]
19. Ivabradine for Treatment of Coronary Artery Disease: From Last Chance Resort to Mainstem of a Reasoned Therapy.
Lupi A; Rognoni A; Cavallino C; Secco GG; Rosso R; Bongo AS
Cardiovasc Hematol Agents Med Chem; 2015; 13(1):4-9. PubMed ID: 25544120
[TBL] [Abstract][Full Text] [Related]
20. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
Böhm M; Robertson M; Ford I; Borer JS; Komajda M; Kindermann I; Maack C; Lainscak M; Swedberg K; Tavazzi L
Am J Cardiol; 2015 Dec; 116(12):1890-7. PubMed ID: 26508709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
